ABCL vs MANE
AbCellera Biologics Inc. vs Veradermics, Incorporated — AI-powered side-by-side comparison
ABCL
AbCellera Biologics Inc.
64
Buy
VS
MANE
Veradermics, Incorporated
67
Buy
| Metric | ABCL | MANE |
|---|
| AI Score |
64
|
67
|
| Price |
$10.98
|
$111.00
|
| P/E Ratio |
-19.18×
|
-69.90×
|
| ROE |
-15.1%
|
57.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.0%
|
0.0%
|
| Debt / Equity |
0.15×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
91.5
|
48.6
|
| Beta |
1.191
|
1.3492
|
| Expected Upside |
—
|
+6.7%
|
AI Committee View
Current Innellis committee reasoning for ABCL versus MANE.
MANE leads by 3 points.
MANE scores 67/100 (Buy) versus ABCL at 64/100 (Buy).
ABCL Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- RSI at 91 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
MANE Committee View
80% agreement
5 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical